JP2011188872A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011188872A5 JP2011188872A5 JP2011148711A JP2011148711A JP2011188872A5 JP 2011188872 A5 JP2011188872 A5 JP 2011188872A5 JP 2011148711 A JP2011148711 A JP 2011148711A JP 2011148711 A JP2011148711 A JP 2011148711A JP 2011188872 A5 JP2011188872 A5 JP 2011188872A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- cell
- interleukin
- dendritic cells
- immature dendritic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 32
- 108091007433 antigens Proteins 0.000 claims 32
- 102000036639 antigens Human genes 0.000 claims 32
- 210000004443 dendritic cell Anatomy 0.000 claims 31
- 238000000034 method Methods 0.000 claims 22
- 238000000338 in vitro Methods 0.000 claims 10
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 6
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 6
- 102000004388 Interleukin-4 Human genes 0.000 claims 6
- 108090000978 Interleukin-4 Proteins 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 230000001580 bacterial effect Effects 0.000 claims 6
- 230000004069 differentiation Effects 0.000 claims 6
- 229940028885 interleukin-4 Drugs 0.000 claims 6
- 239000002243 precursor Substances 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 230000035800 maturation Effects 0.000 claims 4
- 102000003814 Interleukin-10 Human genes 0.000 claims 3
- 108090000174 Interleukin-10 Proteins 0.000 claims 3
- 102000013462 Interleukin-12 Human genes 0.000 claims 3
- 108010065805 Interleukin-12 Proteins 0.000 claims 3
- 102000003816 Interleukin-13 Human genes 0.000 claims 3
- 108090000176 Interleukin-13 Proteins 0.000 claims 3
- 239000013592 cell lysate Substances 0.000 claims 3
- 238000012258 culturing Methods 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000012528 membrane Substances 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 210000004881 tumor cell Anatomy 0.000 claims 3
- 102000008070 Interferon-gamma Human genes 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 229960003130 interferon gamma Drugs 0.000 claims 2
- 210000005260 human cell Anatomy 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 229940076144 interleukin-10 Drugs 0.000 claims 1
- 229940117681 interleukin-12 Drugs 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31759201P | 2001-09-06 | 2001-09-06 | |
| US60/317,592 | 2001-09-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003526345A Division JP2005505270A (ja) | 2001-09-06 | 2002-09-06 | 単球性樹状細胞およびｔ細胞にｔｈ−１応答をプライミングするための組成物および方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015040165A Division JP6114768B2 (ja) | 2001-09-06 | 2015-03-02 | 単球性樹状細胞およびｔ細胞にｔｈ−１応答をプライミングするための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011188872A JP2011188872A (ja) | 2011-09-29 |
| JP2011188872A5 true JP2011188872A5 (enExample) | 2012-10-18 |
| JP5777956B2 JP5777956B2 (ja) | 2015-09-16 |
Family
ID=32654226
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003526345A Pending JP2005505270A (ja) | 2001-09-06 | 2002-09-06 | 単球性樹状細胞およびｔ細胞にｔｈ−１応答をプライミングするための組成物および方法 |
| JP2011148711A Expired - Fee Related JP5777956B2 (ja) | 2001-09-06 | 2011-07-04 | 単球性樹状細胞およびｔ細胞にｔｈ−１応答をプライミングするための組成物および方法 |
| JP2015040165A Expired - Fee Related JP6114768B2 (ja) | 2001-09-06 | 2015-03-02 | 単球性樹状細胞およびｔ細胞にｔｈ−１応答をプライミングするための組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003526345A Pending JP2005505270A (ja) | 2001-09-06 | 2002-09-06 | 単球性樹状細胞およびｔ細胞にｔｈ−１応答をプライミングするための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015040165A Expired - Fee Related JP6114768B2 (ja) | 2001-09-06 | 2015-03-02 | 単球性樹状細胞およびｔ細胞にｔｈ−１応答をプライミングするための組成物および方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20050059151A1 (enExample) |
| EP (3) | EP1441591B1 (enExample) |
| JP (3) | JP2005505270A (enExample) |
| KR (3) | KR101803702B1 (enExample) |
| CN (2) | CN1636229B (enExample) |
| AU (1) | AU2008221592B2 (enExample) |
| BR (1) | BRPI0212545B8 (enExample) |
| CA (1) | CA2459713C (enExample) |
| DK (2) | DK1441591T3 (enExample) |
| ES (2) | ES2766299T3 (enExample) |
| IL (3) | IL160720A0 (enExample) |
| MX (1) | MXPA04002147A (enExample) |
| NO (2) | NO338147B1 (enExample) |
| NZ (1) | NZ531530A (enExample) |
| PL (1) | PL372098A1 (enExample) |
| PT (2) | PT1441591T (enExample) |
| WO (1) | WO2003022215A2 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT412145B (de) * | 2002-09-13 | 2004-10-25 | Forsch Krebskranke Kinder | Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen |
| US20040057935A1 (en) * | 2002-09-20 | 2004-03-25 | Cedars-Sinai Medical Center | Intratumoral delivery of dendritic cells |
| WO2004053072A2 (en) * | 2002-12-06 | 2004-06-24 | Northwest Biotherapeutics, Inc. | Administration of dendritic cells partially matured in vitro for the treatment of tumors |
| KR20110106474A (ko) * | 2003-02-27 | 2011-09-28 | 노쓰웨스트 바이오써라퓨틱스, 인크. | 부가의 사이토킨의 부재하에 ｇｍ-ｃｓｆ를 사용한 단핵구 수지상 전구체 세포로부터의 수지상 세포 생성방법 |
| EP1484064A1 (en) | 2003-06-04 | 2004-12-08 | Gesellschaft für Biotechnologische Forschung | Therapeutical composition containing dentritic cells and use thereof |
| EP1670513B1 (en) * | 2003-10-06 | 2013-01-23 | Cedars-Sinai Medical Center | Cox-2 inhibitors and dendritic cells for use in the treatment of cancer. |
| WO2005043155A1 (en) * | 2003-10-21 | 2005-05-12 | Cedars-Sinai Medical Center | System and method for the treatment of cancer, including cancers of the central nervous system |
| US20070269414A1 (en) * | 2003-11-04 | 2007-11-22 | Shinji Okano | Method for Producing Gene Transferred Denritic Cells |
| EP1775342A4 (en) | 2004-06-24 | 2007-11-07 | Dnavec Research Inc | ANTITUM-AGENT WITH MINUS STRAND RNA VIRUS |
| RU2008122550A (ru) * | 2005-12-08 | 2010-01-20 | Норсуэст Байотерапьютикс, Инк. (Us) | Композиции и способы индуцирования активации незрелых моноцитарных дендритных клеток |
| EP1840206A1 (en) * | 2006-03-28 | 2007-10-03 | Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh | Compositions for the preparation of mature dendritic cells |
| EP2084267B1 (en) | 2006-09-26 | 2018-04-11 | Cedars-Sinai Medical Center | Cancer stem cell antigen vaccines and methods |
| US8871211B2 (en) | 2006-09-28 | 2014-10-28 | Cedars-Sinai Medical Center | Cancer vaccines and vaccination methods |
| EP2328923B1 (en) | 2008-09-02 | 2016-01-13 | Cedars-Sinai Medical Center | Cd133 epitopes |
| PT2427485T (pt) | 2009-05-07 | 2017-03-13 | Immunocellular Therapeutics Ltd | Epitopos cd133 |
| GB201414403D0 (en) * | 2012-02-02 | 2014-10-01 | California Stem Cell Inc | Pluripotent germ layer origin antigen presenting cancer vaccine |
| US9701942B2 (en) | 2012-05-31 | 2017-07-11 | Jw Creagene Inc. | Composition for maturing dendritic cells, and method for preparing antigen-specific dendritic cells using same |
| AU2020203845C1 (en) * | 2012-09-06 | 2022-08-11 | Orbis Health Solutions, Llc | Tumor lysate loaded particles |
| US9744193B2 (en) * | 2012-09-06 | 2017-08-29 | Orbis Health Solutions Llc | Tumor lysate loaded particles |
| AU2013359392C1 (en) | 2012-12-12 | 2016-12-08 | Orbis Health Solutions, Llc | Compositions and methods for tissue regeneration |
| US20140234351A1 (en) | 2013-02-14 | 2014-08-21 | Immunocellular Therapeutics, Ltd. | Cancer vaccines and vaccination methods |
| CN104936612B (zh) * | 2013-09-05 | 2021-01-01 | 奥比思健康解决方案有限责任公司 | 装载了肿瘤裂解物的微粒 |
| CA3099413A1 (en) | 2014-03-05 | 2015-09-11 | Orbis Health Solutions Llc | Vaccine delivery systems using yeast cell wall particles |
| US10373259B1 (en) | 2014-05-20 | 2019-08-06 | State Farm Mutual Automobile Insurance Company | Fully autonomous vehicle insurance pricing |
| US10599155B1 (en) | 2014-05-20 | 2020-03-24 | State Farm Mutual Automobile Insurance Company | Autonomous vehicle operation feature monitoring and evaluation of effectiveness |
| US9972054B1 (en) | 2014-05-20 | 2018-05-15 | State Farm Mutual Automobile Insurance Company | Accident fault determination for autonomous vehicles |
| US10181161B1 (en) | 2014-05-20 | 2019-01-15 | State Farm Mutual Automobile Insurance Company | Autonomous communication feature use |
| US11669090B2 (en) | 2014-05-20 | 2023-06-06 | State Farm Mutual Automobile Insurance Company | Autonomous vehicle operation feature monitoring and evaluation of effectiveness |
| US10540723B1 (en) | 2014-07-21 | 2020-01-21 | State Farm Mutual Automobile Insurance Company | Methods of providing insurance savings based upon telematics and usage-based insurance |
| US9946531B1 (en) | 2014-11-13 | 2018-04-17 | State Farm Mutual Automobile Insurance Company | Autonomous vehicle software version assessment |
| WO2017002045A1 (en) | 2015-06-30 | 2017-01-05 | Stemlab, Sa | A viable cell population, method for production and uses thereof |
| KR102763373B1 (ko) * | 2015-06-30 | 2025-02-07 | 노쓰웨스트 바이오써라퓨틱스, 인크. | 향상되거나 증가된 항-종양 면역 반응을 유도하는 최적으로 활성화된 수지상 세포 |
| US9805601B1 (en) | 2015-08-28 | 2017-10-31 | State Farm Mutual Automobile Insurance Company | Vehicular traffic alerts for avoidance of abnormal traffic conditions |
| US10324463B1 (en) | 2016-01-22 | 2019-06-18 | State Farm Mutual Automobile Insurance Company | Autonomous vehicle operation adjustment based upon route |
| US10134278B1 (en) | 2016-01-22 | 2018-11-20 | State Farm Mutual Automobile Insurance Company | Autonomous vehicle application |
| US11719545B2 (en) | 2016-01-22 | 2023-08-08 | Hyundai Motor Company | Autonomous vehicle component damage and salvage assessment |
| US11062414B1 (en) | 2016-01-22 | 2021-07-13 | State Farm Mutual Automobile Insurance Company | System and method for autonomous vehicle ride sharing using facial recognition |
| US11441916B1 (en) | 2016-01-22 | 2022-09-13 | State Farm Mutual Automobile Insurance Company | Autonomous vehicle trip routing |
| US10395332B1 (en) | 2016-01-22 | 2019-08-27 | State Farm Mutual Automobile Insurance Company | Coordinated autonomous vehicle automatic area scanning |
| US11242051B1 (en) | 2016-01-22 | 2022-02-08 | State Farm Mutual Automobile Insurance Company | Autonomous vehicle action communications |
| KR102038114B1 (ko) * | 2016-02-26 | 2019-10-30 | 주식회사 엘지화학 | 광학 점착제용 (메타)아크릴레이트기 함유 벤조페논의 제조방법 및 광학 점착제 조성물 |
| WO2018160666A1 (en) * | 2017-02-28 | 2018-09-07 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Short-term activated dc1s and methods for their production and use |
| WO2019183924A1 (en) * | 2018-03-30 | 2019-10-03 | Syz Cell Therapy Co. | Improved multiple antigen specific cell therapy methods |
| CN115461073A (zh) * | 2019-10-07 | 2022-12-09 | 西北生物治疗药物公司 | 用于增强树突细胞和T细胞激活以及用于诱导Th-1免疫应答的体外方法和组合物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5162504A (en) | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
| US5366866A (en) * | 1991-07-25 | 1994-11-22 | Duke University | Method of diagnosing ovarian and endometrial cancer with monoclonal antibodies OXA and OXB |
| US5227471A (en) * | 1992-01-30 | 1993-07-13 | Eastern Virginia Medical School Of The Medical College Of Hampton Roads | Monoclonal antibody PD41 that binds to a prostate mucin antigen that is expressed in human prostatic carcinoma |
| US5788963A (en) | 1995-07-31 | 1998-08-04 | Pacific Northwest Cancer Foundation | Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy |
| CN1172718C (zh) * | 1995-10-04 | 2004-10-27 | 依默耐克斯有限公司 | 树突状细胞刺激因子 |
| US7659119B2 (en) * | 1996-02-12 | 2010-02-09 | Argos Therapeutics, Inc. | Method and compositions for obtaining mature dendritic cells |
| US6274378B1 (en) * | 1997-10-27 | 2001-08-14 | The Rockefeller University | Methods and compositions for obtaining mature dendritic cells |
| JP2000143534A (ja) * | 1998-11-13 | 2000-05-23 | Asahi Chem Ind Co Ltd | 樹状細胞ワクチン及びその製造方法 |
| JP2000279181A (ja) * | 1999-04-01 | 2000-10-10 | Japan Science & Technology Corp | ヒト樹状細胞の発現遺伝子群 |
| EP1254953A4 (en) * | 1999-12-28 | 2004-06-02 | Toyoshima Kumao | Maturity-triggering agent for immature dendritic cells |
| US6247378B1 (en) * | 2000-01-06 | 2001-06-19 | Deere & Company | Operator control device for an infinitely variable transmission |
| EP2363139B1 (en) * | 2000-05-12 | 2016-03-02 | NorthWest Biotherapeutics, Inc. | Method to increase class I presentation of exogenous antigens by human dendritic cells |
| ATE317428T1 (de) * | 2001-01-15 | 2006-02-15 | Idm Immuno Designed Molecules | Verfahren zur herstellung von submikropartikel- suspensionen pharmazeutischer substanzen |
| WO2003010292A2 (en) * | 2001-07-25 | 2003-02-06 | Northwest Biotherapeutics, Inc. | Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors |
-
2002
- 2002-09-06 NZ NZ531530A patent/NZ531530A/en not_active IP Right Cessation
- 2002-09-06 ES ES10181985T patent/ES2766299T3/es not_active Expired - Lifetime
- 2002-09-06 EP EP02761594.7A patent/EP1441591B1/en not_active Expired - Lifetime
- 2002-09-06 KR KR1020147023675A patent/KR101803702B1/ko not_active Expired - Lifetime
- 2002-09-06 MX MXPA04002147A patent/MXPA04002147A/es active IP Right Grant
- 2002-09-06 WO PCT/US2002/028620 patent/WO2003022215A2/en not_active Ceased
- 2002-09-06 PT PT2761594T patent/PT1441591T/pt unknown
- 2002-09-06 BR BRPI0212545A patent/BRPI0212545B8/pt not_active IP Right Cessation
- 2002-09-06 EP EP10181985.2A patent/EP2322603B1/en not_active Expired - Lifetime
- 2002-09-06 CN CN028198174A patent/CN1636229B/zh not_active Expired - Fee Related
- 2002-09-06 DK DK02761594.7T patent/DK1441591T3/en active
- 2002-09-06 KR KR1020117012621A patent/KR20110081341A/ko not_active Ceased
- 2002-09-06 JP JP2003526345A patent/JP2005505270A/ja active Pending
- 2002-09-06 PL PL02372098A patent/PL372098A1/xx not_active Application Discontinuation
- 2002-09-06 DK DK10181985.2T patent/DK2322603T3/da active
- 2002-09-06 US US10/488,744 patent/US20050059151A1/en not_active Abandoned
- 2002-09-06 CN CN201210470111.XA patent/CN102973928B/zh not_active Expired - Fee Related
- 2002-09-06 ES ES02761594.7T patent/ES2598109T3/es not_active Expired - Lifetime
- 2002-09-06 IL IL16072002A patent/IL160720A0/xx unknown
- 2002-09-06 PT PT101819852T patent/PT2322603T/pt unknown
- 2002-09-06 CA CA2459713A patent/CA2459713C/en not_active Expired - Lifetime
- 2002-09-06 KR KR1020047003386A patent/KR20050027163A/ko not_active Ceased
- 2002-09-06 EP EP19202820.7A patent/EP3653055A1/en not_active Withdrawn
-
2004
- 2004-03-03 IL IL160720A patent/IL160720A/en active IP Right Grant
- 2004-03-05 NO NO20040965A patent/NO338147B1/no not_active IP Right Cessation
-
2008
- 2008-05-29 US US12/129,549 patent/US20080254064A1/en not_active Abandoned
- 2008-09-19 AU AU2008221592A patent/AU2008221592B2/en not_active Ceased
-
2011
- 2011-07-04 JP JP2011148711A patent/JP5777956B2/ja not_active Expired - Fee Related
-
2012
- 2012-04-18 IL IL219266A patent/IL219266A/en active IP Right Grant
-
2015
- 2015-03-02 JP JP2015040165A patent/JP6114768B2/ja not_active Expired - Fee Related
- 2015-11-16 NO NO20151562A patent/NO20151562A1/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011188872A5 (enExample) | ||
| JP2005505270A5 (enExample) | ||
| Urdahl et al. | Initiation and regulation of T-cell responses in tuberculosis | |
| Rao et al. | Tumor‐derived exosomes elicit tumor suppression in murine hepatocellular carcinoma models and humans in vitro | |
| JP2014511704A5 (enExample) | ||
| IL273516B1 (en) | Methods for isolating T cells with antigenic specificity for a cancer-specific P53 mutation | |
| Yanagibashi et al. | Bacteroides induce higher IgA production than Lactobacillus by increasing activation-induced cytidine deaminase expression in B cells in murine Peyer’s patches | |
| JP2013533745A5 (enExample) | ||
| CN103533955A (zh) | 用于激发t细胞的方法 | |
| JPWO2020243561A5 (enExample) | ||
| AR107278A1 (es) | Procedimientos de producción de linfocitos t y linfocitos t producidos por ellos | |
| JP2012518409A5 (enExample) | ||
| Hou et al. | Host response to Sendai virus in mice lacking class II major histocompatibility complex glycoproteins | |
| JP2011500592A5 (enExample) | ||
| JP2011525191A5 (enExample) | ||
| WO2022052984A1 (en) | Universal sars-cov-2 vaccine and preparation method thereof | |
| Larssen et al. | Allogenicity boosts extracellular vesicle–induced antigen-specific immunity and mediates tumor protection and long-term memory in vivo | |
| Bergot et al. | New approaches to immunotherapy for HPV associated cancers | |
| JP2020534313A5 (enExample) | ||
| JP2010538649A5 (enExample) | ||
| Shi et al. | Hepatitis B virus (HBV) antigen-pulsed monocyte-derived dendritic cells from HBV-associated hepatocellular carcinoma patients significantly enhance specific T cell responses in vitro | |
| JP2010538619A5 (enExample) | ||
| JP2011522835A5 (enExample) | ||
| Gedvilaite et al. | Virus-like particles derived from major capsid protein VP1 of different polyomaviruses differ in their ability to induce maturation in human dendritic cells | |
| Ni et al. | Antitumor vaccination by Newcastle Disease Virus Hemagglutinin–Neuraminidase plasmid DNA application: Changes in tumor microenvironment and activation of innate anti-tumor immunity |